Crf1 Receptor Antagonists For The Treatment Of Congenital Adrenal Hyperplasia

Patent No. EP3096756 (titled "Crf1 Receptor Antagonists For The Treatment Of Congenital Adrenal Hyperplasia") was filed by Neurocrine Biosciences on Jan 21, 2015. The application was issued on Jun 12, 2024.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
KRAUS & LEDERER PARTGMBBMar 7, 2025KRAUS & LEDERER PARTGMBB

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3096756

NEUROCRINE BIOSCIENCES
Application Number
EP15702917A
Filing Date
Jan 21, 2015
Status
Granted And Under Opposition
May 10, 2024
Publication Date
Jun 12, 2024